Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Crystal Structures Define Mode of Action of Bacteriophage Endolysins

By BiotechDaily International staff writers
Posted on 13 Aug 2014
Image: Electron microscopy image of the bacteriophages investigated (Photo courtesy of the European Molecular Biology Laboratory).
Image: Electron microscopy image of the bacteriophages investigated (Photo courtesy of the European Molecular Biology Laboratory).
Image: The analyzed endolysins are activated by switching from a tensed, stretched state (left) to a relaxed state (right) (Photo courtesy of the European Molecular Biology Laboratory).
Image: The analyzed endolysins are activated by switching from a tensed, stretched state (left) to a relaxed state (right) (Photo courtesy of the European Molecular Biology Laboratory).
New antibacterial agents based on bacteriophages or their endolysin enzymes have been proposed to solve the problem of the bacterium Clostridium difficile, which is becoming a serious health hazard in hospitals and healthcare institutes, due to its resistance to antibiotics.

Investigators at the European Molecular Biology Laboratory (Hamburg, Germany) based their research primarily on the bacteriophage CD27, which is capable of lysing C. difficile. In addition, they worked with a recombinant form of the CD27L endolysin, which lyses C. difficile in vitro.

To better understand how the lysis process works, the investigators determined the three-dimensional structures of the CD27L endolysin and the CTP1L endolysin from the closely related bacteriophage CPT1 that targets C. tyrobutyricum. For this task they employed X-ray crystallography and small angle X-ray scattering (SAXS), which was done at the Deutsches Elektronen-Synchrotron (DESY).

Results published in the July 24, 2014, online edition of the journal PLOS Pathogens revealed that the two endolysins shared a common activation mechanism, despite having been taken from different species of Clostridium. The activation mechanism depended on a structure where an extended dimer existed in the inactive state but switched to a side-by-side "relaxed" morphology in the active state, which triggered the cleavage of the C-terminal domain. This change of morphology led to the release of the catalytic portion of the endolysin, enabling the efficient digestion of the bacterial cell wall.

“These enzymes appear to switch from a tense, elongated shape, where a pair of endolysins is joined together, to a relaxed state where the two endolysins lie side-by-side,” said first author Dr. Matthew Dunne, a researcher at the European Molecular Biology Laboratory. “The switch from one conformation to the other releases the active enzyme, which then begins to degrade the cell wall.”

Related Links:

European Molecular Biology Laboratory



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.